[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"surveillance-colonoscopy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:surveillance-colonoscopy":76},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100622077",false,"NCT07378930","ULTRA-high-risk Surveillance to Avoid Future Events: the ULTRA-SAFE Trial","ULTRA-SAFE","Inclusion Criteria:\n\n1. Age: Adults aged 40 to 75 years.\n2. Initial Colonoscopy Findings: Detection and removal of at least two advanced adenomas during the baseline colonoscopy.\n3. Adherence: Willingness to comply with the assigned screening protocol, including fecal immunochemical testing (FIT) and follow-up colonoscopies\n\nExclusion Criteria:\n\n1. Age: Individuals younger than 40 or older than 75 years.\n2. High-Risk Predispositions: Patients with inflammatory bowel disease (IBD), Familial Adenomatous Polyposis (FAP), or a documented hereditary colorectal cancer syndrome (e.g., Lynch syndrome).\n3. Cancer History: A history of colorectal cancer (excluding carcinoma in situ).\n4. Contraindications: Patients for whom polypectomy is clinically inappropriate or unsafe.\n5. Adenoma Count\u002FType: Failure to meet the requirement of at least two advanced adenomas during the initial colonoscopy.\n\n7.Extensive Low-Risk Lesions: Presence of more than ten low-risk adenomas.\n\n8.Pregnancy: Currently pregnant individuals.","ALL","40 Years","75 Years",{"count":19,"type":20},940,"ESTIMATED","INTERVENTIONAL",[23],"NA","The ULTRA-SAFE clinical trial is a prospective, randomized study designed to address the limitations of current \"one-size-fits-all\" colorectal cancer surveillance guidelines. While international standards recommend a three-year follow-up colonoscopy for all high-risk patients, data suggests that those with multiple advanced adenomas face a significantly higher recurrence risk (20%) compared to those with only low-risk adenomas (9%). To provide more personalized care, the trial compares a Standard Arm (colonoscopy at year three) against a FIT Arm, where participants undergo annual fecal immunochemical testing in years one and two. A positive FIT triggers an earlier colonoscopy, with the goal of reducing the 3-year prevalence of metachronous advanced colorectal neoplasms (meta-ACRN) from 20% to approximately 12.7%. The study has enrolled roughly 940 participants to statistically validate whether this early screening intervention can effectively prevent future malignant events in ultra-high-risk populations.",[26,27,28],"Colorectal Neoplasms","Colorectal Cancer Prevention","Surveillance Colonoscopy",[30,31,32,33],"Colonoscopy surveillance","Colorectal cancer prevention","Post-polypectomy surveillance","Fecal immunochemical test","NOT_YET_RECRUITING","2026-01-23",{"date":37,"type":38},"2026-01-30","ACTUAL",{"date":40,"type":20},"2026-03-01",{"date":42,"type":20},"2031-05-01",{"name":44,"class":45},"National Taiwan University Hospital","OTHER",{"id":47,"slug":4,"hasResults":10,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":15,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100559775","NCT06568523","Study to Evaluate the Diagnostic Performance of of MAGENTIQ-COLO During Colonoscopy.","A Multicenter Study to Evaluate the Diagnostic Performance of Computer-aided Polyp Size Classification of the MAGENTIQ-COLO During Real-time Colonoscopy","Inclusion Criteria:\n\n* Individuals aged ≥45 - ≤80 years old, who are scheduled for non-iFOBT screening or surveillance colonoscopy.\n\nExclusion Criteria:\n\n1. In situ polyps with known histology detected in a previous colonoscopy.\n2. No colorectal polyps detected during colonoscopy.\n3. Known or suspected inflammatory bowel disease.\n4. Polyposis syndrome (e.g., familial adenomatous polyposis, serrated polyposis).\n5. Non-hereditary polyposis syndromes (e.g. Lynch syndrome).\n6. History of chemotherapy or radiation therapy for colorectal lesions.\n7. Pregnancy.\n8. Has a referral for therapeutic procedure (i.e., endoscopic mucosal resection, intervention to stop a lower gastro-intestinal bleeding, etc.).\n9. Inability to undergo polypectomy (e.g., incorrect continued use of anticoagulants, comorbidities) or patient refusal, as assessed by the endoscopist.\n10. Inability to provide informed consent.",true,"45 Years","80 Years",{"count":56,"type":20},330,[23],"This is an international, multicenter, study to evaluate the diagnostic performance of the CADx polyp sizing modality of the MAGENTIQ-COLO.",[60,28],"Screening Colonoscopy",[26,62,63,60,28,64],"Intestinal Neoplasms","Digestive System Neoplasms","Automatic Polyp Detection","2024-08-21",{"date":67,"type":38},"2024-08-23",{"date":69,"type":20},"2024-09-15",{"date":71,"type":20},"2025-08-31",{"name":73,"class":74},"Magentiq Eye LTD","INDUSTRY",5,""]